title: Effect of rectal administration of rebamipide on dextran sulfate sodium-induced colitis: role of hepatocyte growth factor.
abstract: OBJECTIVE
  Since rebamipide is effective for the treatment of ulcerative colitis (UC), we examined the involvement of hepatocyte growth factor (HGF) in the action of rebamipide.
  
  
  METHODS
  Fifty-five and forty female Balb/c mice, respectively, were used in Exp. 1 and 2.
  
  
  METHODS
  50 mg/kg/day rebamipide (Exp. 1) and 1 x 10(7) pfu pAxCAHGF (the CAG promoter-driving HGF gene in adenovirus vector) (Exp. 2) were intrarectally introduced after induction of colitis by 4 % dextran sulfate sodium (DSS).
  
  
  METHODS
  Therapeutic effects were assessed by cell proliferation and apoptosis.
  
  
  RESULTS
  Rebamipide caused proliferation of epithelial cells at 10 days after treatment, and decreased apoptosis at 10, 14 and 21 days, compared with controls. Expression of HGF was greatly increased in rebamipide-treated mice. pAxCAHGF caused cell proliferation and apoptosis, which showed the same pattern as with rebamipide treatment.
  
  
  CONCLUSIONS
  Rectal administration of rebamipide is effective for DSS-induced colitis in association with induction of HGF.
authors.affiliation: Division of Molecular and Genetic Medicine, Department of Genetic Medicine and Regenerative Therapeutics, Graduate School of Medicine, Tottori University, Yonago 683-8504, Japan.
authors.forename: R
authors.initials: R
authors.lastname: Murai
authors.forename: T
authors.initials: T
authors.lastname: Kanbe
authors.forename: T
authors.initials: T
authors.lastname: Mukoyama
authors.forename: T
authors.initials: T
authors.lastname: Shimomura
authors.forename: K
authors.initials: K
authors.lastname: Hashiguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Yoshida
authors.forename: H
authors.initials: H
authors.lastname: Tsuchiya
authors.forename: Y
authors.initials: Y
authors.lastname: Hoshikawa
authors.forename: A
authors.initials: A
authors.lastname: Kurimasa
authors.forename: G
authors.initials: G
authors.lastname: Shiota
mesh_terms: D000285:Administration, Rectal; D000409:Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000818:Animals; D000925:Anticoagulants / Q000633:toxicity; D017209:Apoptosis; D049109:Cell Proliferation; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D016264:Dextran Sulfate / Q000633:toxicity*; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D004847:Epithelial Cells / Q000166:cytology; D005260:Female; D017228:Hepatocyte Growth Factor / Q000378:metabolism*; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D051379:Mice; D008807:Mice, Inbred BALB C; D015363:Quinolones / Q000008:administration & dosage*
chemical_list: D000925:Anticoagulants; D004791:Enzyme Inhibitors; D015363:Quinolones; D017228:Hepatocyte Growth Factor; D016264:Dextran Sulfate; C052785:rebamipide; D000409:Alanine